iBio's IBIO-610 Preserves Muscle in Obese Primates, Cutting Lean Mass Loss to 6%
IBIO sits 15% above its 52-week low of $0.781.
Summary
iBio presented new NHP data showing IBIO-610, its Activin E antibody, combined with semaglutide reduced lean mass loss to 6% of total weight lost versus 22% for semaglutide alone. Fat accounted for 93% of weight lost in the combination group. The company plans first-in-human trials in H1 2027. This is the first disclosure of these body-composition results and the clinical timeline, building on prior data showing 97% Activin E reduction and a 33.2-day half-life. The data supports a differentiated obesity asset targeting muscle preservation, a key concern with GLP-1 therapies.
At the time of this announcement, IBIO was trading at $0.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $55M. The 52-week trading range was $0.78 to $3.82. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.